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ABSTRACT 
 
The oral surgeons are frequently asked to manage patients who are receiving oral anticoagulants. The 
aim of treatment is to minimize the risk of hemorrhage while continuing to protect the patient against 
thromboembolism formation. The ordinary treatment includes the interruption of anticoagulant therapy 
before oral surgery interventions to prevent hemorrhage. Aim of this study is to review the evidence of 
different therapy approach, to highlight the areas of major concern, and to suggest specific oral surgery 
treatment for patients on new oral anticoagulants. A Medline and extensive hand search were performed on 
English-language publications beginning in 1960 till now. Several evolving clinical practices in the last years 
have been detected: anticoagulants are generally not discontinued; oral surgery is performed despite 
laboratory values showing significant bleeding tendency; new effective local hemostatic modalities are used to 
prevent bleeding. It is too early to make comments on how to choose among the different new anticoagulants, 
not only because no head-to-head comparative study has been yet performed, but also because the currently 
available data are insufficient to make a meaningful choice possible. 
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INTRODUCTION 
 
Arterial and venous thrombo embolism is still the most frequent cause of morbidity and mortality in 
high- and middle-income countries, as well as in emerging economies. Excessive activation of coagulation or 
inhibition of anticoagulant mechanisms may result in hypercoagulability and thrombosis. Injury to the vessel 
wall, alterations in blood flow, and changes in the composition of blood are major factors leading to 
thrombosis [1]. 
 
The dentist today is seeing increased numbers ofpatients with chronic medical illnesses. Among 
thesepatients are those that are being treated with anticoagulantdrugs or antiplatelet agents to prevent 
venous orarterial thrombosis. A major concern in the managementof dental patients taking antithrombotic 
agents isthe potential for excessive bleeding after invasivedental procedures [2].The pathologic basis of 
arterial thrombosis involvesatherosclerotic vascular disease associated withplatelet thrombi. Thrombin is a 
major mediator in thistype of thrombosis. Drug therapyof arterial thrombiinvolves agents with antithrombin 
and antiplateletactivity. Venous thrombi usually occur in the presenceof a normal vessel wall, with stasis or 
hypercoagulabilitybeing the major predisposing factors. Drugs thatprevent thrombin formation or lyse fibrin 
clots are themajor agents used in the treatment of venous thrombi. 
 
Aim of this study is to review the evidence of different therapy approach, to highlight the areas of 
major concern, and to suggest specific oral surgery treatment for patients on new oral anticoagulants. A 
Medline and an extensive hand search were performed on English-language publications beginning in 1960 till 
now. The pertinent literature and clinical protocols of hospital dentistry departments have been extensively 
reviewed, presented and discussed.  
 
Oral anticoagulants – withdraw or continuing  
 
The term oral anticoagulant (OAC) refers to oral vitamin K antagonists, including mainly sodium 
warfarin (the most widely used agent in Anglo-Saxon countries) and acenocoumarol (widely used in some 
countries of Europe) [3]. Oral anticoagulants are the group of drugs used to treatmany cardiovascular diseases. 
The vitamin K antagonists, among whichare warfarin and acenocoumarol, have low therapeuticindex as its 
pharmacological management is difficultand need continuous monitoring, also have multipleinteractions with 
other drugs and food. Many of thepatients being treated with warfarin have an inadequateanticoagulation [4]. 
The oral and maxillofacial surgeons are frequently asked to manage patients who are receiving oral 
anticoagulants. The goal of treatment is to minimize the risk of hemorrhage while continuing to protect the 
patient against thromboembolism formation. The ordinary treatment includes the interruption of 
anticoagulant therapy for oral surgery interventions to prevent hemorrhage. Thus, this issue is still 
controversial [5-7]. 
 
The anticoagulant effect in turn depends on the half-life of the inhibited factors. In this sense, the 
half-lives of factors VII, IX, X and II are 6, 24, 40 and 60 hours, respectively. Blood coagulation factor VII is the 
first to be affected, prolonging prothrombin time (PT). Factors IX, X and II are posterior affected: factor IX 
prolongs activated partial thromboplastin time (aPTT), while factors X and II prolong both PT and aPTT. These 
are well tolerated drugs, with rapid absorption via the oral route. The peak plasma concentrations are reached 
one hour after administration, though the reduction in coagulation factors takes place 48-72 hours after 
dosing. The half-life of warfarin is 48-72 hours, versus 8-10 hours in the case of acenocoumarol. Thus, the 
effects of warfarin are longer lasting in terms of both the induction and disappearance of therapeutic action [3, 
8-10]. 
 
However, patients who interrupt oral anticoagulants therapy are at risk of developing a 
thromboembolism with or without bridging therapy. On the other hand, oral anticoagulants therapy can be 
continued without interruption for procedures such as dentoalveolar surgeries that rarely cause significant or 
life-threatening bleeding. Stopping oral anticoagulants is problematic because of its slow unpredictable 
reversal [2, 11-14]. 
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Interruption of Oral Anticoagulant Therapy, Risk of Thrombotic Episode and Limitations of Traditional 
Anticoagulants 
 
The risk for thromboembolism depends on several factors, including the clinical indications for 
anticoagulation. Anticoagulation is required in the management of patients with prosthetic heart valves, 
chronic atrial fibrillation, hypercoagulable states (ie, protein C deficiency, protein S deficiency, factor V Leiden 
mutation, antithrombin III deficiency, antiphospholipid-antibody syndrome), venous or arterial 
thromboembolism, and cerebrovascular disease with strokes. However, patients who require anticoagulation 
do not have equal risk of developing thromboembolism [9,14,15]. 
 
The goal of managing anticoagulated patients who need surgery is to prevent major or life-
threatening bleeding while protecting against thromboembolism. Some procedures such as intra-abdominal, 
intrathoracic, major cancer surgery, removal of head and neck tumors, and extra oral open reduction of facial 
fractures are associated with considerable bleeding [9, 16,17].  
 
Some patients are particularly sensitive to OACs, and the activity of these drugs moreover can be 
affected by a range of factors including individual patient response, diet, or the simultaneous administration of 
other commonly used drugs such as antibiotics, analgesics, or even herbal remedies. As a result, regular 
monitoring is required, and such control must be more frequent when changes occur in any of the 
aforementioned aspects. OAC action is monitored on the basis of the effect of such drugs on prothrombin time 
(PT), i.e., the time required for the clotting of citrate-treated plasma, after adding calcium and thromboplastin. 
Thromboplastin is extracted from different tissues with different levels of sensitivity - a fact that complicates 
the comparison of PT test results. The PT results are usually reported as the ratio patient time / control time. 
The simple ratio is extremely variable, depending on the sensitivity of the reagent used - thus making it 
impossible to establish universally applicable therapeutic margins [18].  
 
For this reason, in 1978 the World Health Organization (WHO) recommended PT standardization, and 
in 1983 it introduced the INR (international normalized ratio), which is calculated by raising the simple ratio 
tothe international sensitivity index (ISI) of the thromboplastin used [19]. Thus, INR = (patient time / control 
time) ISI.  
 
This is the formula used to standardize PT, allowing comparison regardless of the thromboplastin 
used by the different laboratories, and ensuring increased reliability in monitoring OAC treatment. At the same 
time, the different international societies established recommendations regarding the therapeutic 
anticoagulation levels to be maintained according to the existing patient pathology - the corresponding INR 
value ranging from 2 to 3.5. Because of that there is a strong correlation between INR and bleeding risk - the 
latter increasing when INR >4 (Table 1).  
 
Table 1: Therapeutic anticoagulation levels 
 
Clinical pathology INR INR 
- Prophylaxis – venous thromboembolism (high risk surgery) 
- Prophylaxis – venous thromboembolism (hip surgery) 
- Treatment of deep venous thrombosis or pulmonary embolism 
- Prevention of systemic embolism in patients with atrial fibrillation, heart valve disease, bio 
prostheses, or acute myocardial infarction 
- Valve prostheses, recurrent systemic embolism, recurrent myocardial 
Infarction 
2.0-3.0 
2.0-3.0 
2.0-3.0 
2.0-3.0 
 
2.5-3.5 
 
INR = International Normalized Ratio 
 
The recommendations vary according to the bleeding risk of the surgical intervention and the 
indication of anticoagulation therapy (i.e., the thromboembolic risk of the patient). Thus, for example, 
treatment to prevent venous thromboembolism is not the same as treatment for dealing with an acute 
thrombotic episode.  
 
Although consensus is lacking, the expert groups [18] do establish a series of recommendations: 
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 For patients at low risk of bleeding after the operation, anticoagulation can be maintained at the 
lower limit of the therapeutic range (INR = 2.0). 
 For patients at high bleeding risk, anticoagulation should be maintained at sub therapeutic levels (INR 
= 1.5).  
 
Accordingly, acenocoumarol should be suspended 3-4 days before surgery (4-5 days in the case of 
warfarin). On day -3, low molecular weight heparin (LMWH) should be provided at therapeutic, medium or 
prophylactic doses, depending on whether the thrombotic risk of the patient is high, moderate or low, 
respectively. This is to be maintained until 12 hours before surgery, followed 12 hours after surgery be 
reintroduction of the original treatment, provided there is no bleeding. 
 
In spite of the excellent clinical results obtained with traditional anticoagulants, there is much space 
for improvement in clinical practice in terms of their clinical applicability, safety, and efficacy. The comparative 
advantages and disadvantages of traditional anticoagulants, and the corresponding clinical consequences, are 
summarized in Table 2. 
 
Table 2: Comparative advantages and disadvantages of traditional anticoagulant and corresponding clinical 
consequences 
 
Comparative advantage or disadvantage Consequence 
LMWH versus UH: 
Better bioavailability  
Less binding to endothelium 
 
Less binding to plasma proteins  
 
 
Less binding to platelet factor 4  
Less binding to bone cells  
Protamine sulphate less effective as antidote  
 
Fondaparinux versus LMWH : 
Improved safety lower risk of thrombocytopenia 
and osteoporosis 
Defined target  
 
Less potent inhibition of factor Xa than heparin  
 
Vitamin K antagonists versus LMWH and fondaparinux: 
Oral administration  
Interaction with food, drugs and genetic polymorphisms  
Longer plasma half-life  
 
Subcutaneous administration 
Longer half-life, which permits once-daily 
administration 
More predictable anticoagulant response, which 
obviates need for 
monitoring  
Lower risk of thrombocytopenia 
Lower risk of osteoporosis  
Less rapid reversal in case of overdose and/or 
bleeding complications  
 
No risk of biological contamination;  
 
Single target (factor Xa) versus multiple targets  
Risk of catheter thrombosis in acute coronary 
syndromes, unless supplemental heparin is 
administered 
 
Easier outpatient treatment  
Need of regular laboratory control for dose 
adjustment 
 Less rapid reversal in case of overdose and/or 
bleeding complication 
 
New oral anticoagulants versus traditional 
 
New oral anticoagulants, with distinctly different mechanisms ofaction, are poised to replace the 
vitamin K antagonist (VKAs) and have the potential todramatically change the way we manage patients at risk 
for venousand arterial thromboembolic disease.  
 
In contrast to the VKAs,which target an enzyme in the vitamin K pathway that leads to the reduction 
of the functional levels of factors II, VII, IX, and X, manyof the new agents rely on targeting a particular 
coagulation factorand directly inhibiting it (Table 3)[20].The new oral anticoagulants include dabigatran 
etexilate, which inhibits thrombin, and rivaroxaban, apixaban, and edoxaban, which inhibit factor Xa. 
 
Although the Non-vitamin K antagonist oral anticoagulants (NOACs) are relatively novel and new at 
present, they will not remain so forever [21]. Consequently, several alternative names have been proposed for 
these drugs, as follows [22]:  
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- Target-Specific Oral anticoagulants (TSOCs),  
- Direct Oral AntiCoagulants (DOACs),  
- Oral Direct Inhibitors (ODIs),  
- Non-monitored Oral AntiCoagulants (NOACs),  
- Non-warfarin Oral AntiCoagulants (NOACs),  
- Non- vitamin K antagonist Oral AntiCoagulants (NOACs), etc. 
 
Several evolving clinical practices in the last years have been detected: anticoagulants are generally 
not discontinued; oral surgery is performed despite laboratory values showing significant bleeding tendency; 
new effective local hemostatic modalities are used to prevent bleeding; Patients at risk are referred to 
hospital-based clinics [23,24]. 
 
Table 3: Pharmacologic Features and Guide for New Anticoagulants 
 
Pharmacologic Features of Dabigatran Etexilate, Rivaroxaban, and Apixaban 
 Dabigatran Etexilate Apixaban Rivaroxaban 
Target Thrombin Factor Xa Factor Xa 
Prodrug Yes No No 
Dosing Fixed, once daily Fixed, twice daily Fixed, once daily 
Bioavailability (%) 6 50 80 
Monitoring No No No 
Half-life (h) 12-14* 12.7 7-11 
Renal clearance (%) 80 25 65 
Guide to the discontinuation of Pradaxa® before procedures or surgeries 
Renal Function 
(CrCL mL/min) 
Half-life (hours), 
mean (range) 
Timing of Discontinuation Prior to Procedure (Minimum) 
Standard Risk of Bleeding High Risk of Bleeding* 
> 80 13 (11 – 22) 24 hours 2 – 4 days 
50 – 80 15 (12 – 34) 24 hours 2 – 4 days 
30 – 50 18 (13 – 23) > 48 hours > 4 days 
< 30 27 (22 – 35) 48 – 120 hours > 5 days 
 
The patient on Pradaxa® (Dabigatran) may need interruption of therapy for dental work, a medical 
procedure such as colonoscopy, or minor or major surgical procedure [25-27]. 
 
As to when exactly to take the last dose of Pradaxa® before the procedure depends on (a) what type 
of procedure is planned and how much bleeding to expect with it, and (b) whether the patient is at high or low 
risk for thrombosis if he/she is off anticoagulants for some period of time [25]. 
 
Dabigatran eteksilate (Pradaxa) with ATS cod B01AE07 (classification - antithrombotic) Boehringer 
Ingelheim (caps. 75mg and 110 mg) is registered in Macedonia, Serbia and Bulgaria. Rivaroxaban is not 
registered in the region. 
 
Interruption and Limitations of Oral Anticoagulants 
 
The risk for thromboembolism depends on several factors, including the clinical indications for 
anticoagulation: prosthetic heart valves, chronic atrial fibrillation, hypercoagulable states venous or arterial 
thromboembolism, and cerebrovascular disease with strokes. However, patients who require anticoagulation 
do not have equal risk of developing thromboembolism [9, 14, 15]. 
 
Some procedures such as intra-abdominal, intrathoracic, major cancer surgery, removal of head and 
neck tumors, and extra oral open reduction of facial fractures are associated with considerable bleeding [9, 16, 
17]. 
 
For this reason, in 1978 the World Health Organization (WHO) recommended PT standardization, and 
in 1983 it introduced the INR (international normalized ratio), which is calculated by raising the simple ratio to 
the international sensitivity index (ISI) of the thromboplastin used [19]. 
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The recommendations vary according to the bleeding risk of the surgical intervention and the 
indication of anticoagulation therapy. For example, treatment to prevent venous thromboembolism is not the 
same as treatment for dealing with an acute thrombotic episode [18]. 
 
Dental Procedures and Bridging Therapy 
 
Depending on the existing thromboembolic risk, the American Heart Association recommends 
different heparin management regimens for the patients with moderate, high and low thromboembolic risk. In 
general, heparins are not reintroduced before 12 hours post-surgery and dosing is postponed for longer 
periods in the case of evidence of bleeding [28-30]. 
 
Assael [23] said that the hemostasis care of the oral anticoagulated patients is a shared responsibility 
and oral and maxillofacial surgeons, and the hematology/coagulation team huddle to determine the steps. A 
common approach to managing patients with a low risk of thromboembolism needing surgery is to interrupt 
oral anticoagulants therapy for several days before and after surgery. Patients with a high risk of 
thromboembolism commonly stop OA and bridge anticoagulation with unfractionated heparin (UHF) or low-
molecular-weight heparin (LMWH) [8]. 
 
Many dental procedures can be done on full dose anticoagulation. Detailed recommendations as to 
which dental procedures can be done on full dose anticoagulation (teeth cleaning, root canal, one or two teeth 
extractions) and for which the anticoagulant level needs to be reduced have been published. A similar 
approach can likely be taken in patients on Pradaxa®. However, it is also easy to tell the patient not to take 
his/her evening dose of Pradaxa® on the day before the procedure and not to take the morning dose on the 
day of the dental procedure; and then to restart the evening of the day of the procedure. However, 
individualized recommendations need to be given [31,32,33]. 
 
A review by Wahl [32] found little to no risk of significantbleeding following dental surgical 
procedures inpatients with a PT of 1.5 to 2 times normal. Wahl [32] also reported evidence that there was little 
risk of bleeding complications even if the PT is up to 2.5 times normal, and a greater risk of adverse outcome is 
associated with stopping anticoagulation. Life threatening or major bleeding in patients who need high-risk 
surgery is avoided by stopping oral anticoagulants with or without bridging therapy. The Food and Drug 
Administration has not approved bridging therapy with LMWH in patients with prosthetic heart valves, and 
UFH is frequently recommended for bridging therapy in these high-risk patients who develop arterial 
thromboembolism [34-37]. 
 
Oral Surgery Procedures and management of bleeding 
 
Management of oral surgery procedures on patients treated with anticoagulants should be influenced 
by several factors: laboratory values, extent and urgency of the intervention, treating physician’s 
recommendation, available facilities, dentist expertise, and patient’s oral, medical, and general condition and 
atibiotic profilaxis.Procedures including single and multiple dental extractions, full mouth extractions, and 
alveolectomies are associated with very few bleeding episodes in patients who continue oral anticoagulants. 
 
In Sindet–Pedersen’s original article [35] anti-coagulant-treated patients undergoing oral surgery 
were prescribed a 4.8% aqueous solution of tranexamic acid for seven days post-surgery to prevent re-
bleeding secondary to fibrinolysis of the wound clot. The results of the most scientific studies confirm that 
anticoagulation treatment with warfarin need not be withdrawn prior to dental extractions, provided that the 
patients do not have a preoperative INR value greater than 4.0, and local measures including antifibrinolytic 
therapy is instituted [26, 38-40]. 
 
Wahl [32] published a review of perioperative management of patients receiving oral anticoagulants 
in 1998. He summarized the outcome of 2,014 dental surgical procedures in patients who continued oral 
anticoagulation. Serious bleeding occurred in only 12 of the procedures, and 5 of the 12 bleeds were 
associated with INRs above therapeutic levels. Wahl [32] also examined reports including 493 patients who 
discontinued warfarin; 5 of these patients developed serious thromboembolic complication, resulting in 4 
deaths.  
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Martinowitz et al. [41] followed 40 patients having 63 teeth removed without altering the oral 
anticoagulation. Local hemostasis was obtained using a biological adhesive after placing thrombin soaked 
gauze into the socket for 3 minutes. Recently, some authors [17, 32-34] have recommended that most 
anticoagulated patients are capable of withstanding routine, limited, oral surgery procedures without 
additional medical intervention such as an antifibrinolytic mouthwash provided a good surgical technique is 
employed. A 4.8% tranexamic acid mouthwash is effective in controlling local hemostasis in anticoagulated 
patients undergoing dental extractions.  
 
In 2003, Carter et al. [38, 39] conducted a randomized study in patients under oral anticoagulation 
and subjected to extractions without modifying the OAC regimen, and applying two types of hemostatic agents 
(4.8% tranexamic acid and autologous fibrin adhesive). The authors concluded that both approaches are 
effective and safe in controlling post-extraction bleeding.  
 
Autologous fibrin adhesive applied to the socket walls in turn was recommended when the patient 
has difficulties performing rinses correctly [38]. Posterior studies reported the same efficacy in controlling 
hemostasis by applying rinses for only two days. Tranexamic acid has no marketing license in some countries, 
and fibrin adhesives are not recommended by all authors, due to the risk of disease transmission - though such 
systems are subjected to viral inactivation processes - and their high cost. 
 
Post-extraction bleeding is generally controlled by local measures such as socket curettage, suturing, 
and local compression, thanks to easy access to the bleeding zone [42,43]. 
 
When such measures prove insufficient, and the anticoagulation effect must be suppressed, this can 
be done by administering vitamin K. In this sense, intravenous administration elicits faster effects than the oral 
route – the recommended dose being 5-10mg. The use of concentrates of prothrombin complex or fresh 
frozen plasma is reserved for cases of important bleeding.  
 
CONCLUSION 
 
The currently available anticoagulant agents all target thrombin or FXa, either indirectly or directly. 
Thrombin is a logical target because of its multiple roles in coagulation. 
 
The management of oral surgery procedures on patients treated with new anticoagulants should be 
influenced by several factors: laboratory values, extent and urgency of the intervention, treating physician’s 
recommendation, available facilities, dentist expertise, and patient’s oral, medical, and general condition. 
Several evolving clinical practices in the last years have been detected: anticoagulants are generally not 
discontinued; oral surgery is performed despite laboratory values showing significant bleeding tendency; new 
effective local hemostatic modalities are used to prevent bleeding. It is too early to make comments on how to 
choose among the different new anticoagulants, because the currently available data are insufficient to make 
a meaningful choice possible. 
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